| 摘要 |
<p>Compounds of formula I: (I) wherein:R1 represents C3-8 cycloalkyl-Y1-, aryl-Y1-, heteroaryl-Y1-, aryl- G-Y1-, heteroaryl-G-Y1-, C1-6 alkyl-G-Y1-, J1-Y1-, NR21R22-Y1-, NR21R22-CO-Y1- or R23-CONR21-Y1-;Q represents -(CR16R19)(CR18aR19a)t-, wherein t represents an integer from 0 to 3; R2 represents hydrogen or C1-6 alkyl; X represents ethylene or a group of formula CReRf wherein Re and Rf independently represent hydrogen or C1-4 alkyl or Re and Rf may together with the carbon atom to which they are attached form a C3-8 cycloalkyl group; R3 and R4 independently represent hydrogen or C1-4 alkyl; Z represents a bond, CO, SO2, CR9R6(CH2)n, (CH2)nCR9R6, CR9R6(CH2)nO, CR9R6(CH2)nS, CR9R6(CH2)nCO, COCR9R6(CH2)n or SO2CR9R6(CH2)n; R5 represents aryl, heteroaryl or aryl-C2-6 alkenyl-; R6 represents hydrogen, C1-4 alkyl, CONR7R8 or COOC1-6 alkyl; a and b represent 1 or 2, such that a+b represents 2 or 3; G represents -S-, -SO2-, -SO2NR20, -NR20SO2 or -NR20-; n represents an integer from 0 to 4; and salts and solvates thereof are CCR3 receptor antagonists and are thus indicated to be useful in therapy.</p> |
